Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord. 1998;13(2):268–74.CrossRefPubMed
2.
Baron JC, Maziere B, Loc'h C, Sgouropoulos P, Bonnet AM, Agid Y. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet. 1985;1:1163–4.
3.
Baron JC, Maziere B, Loc’h C, Cambon H, Sgouropoulos P, Bonnet AM, et al. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab. 1986;6:131–6.CrossRefPubMed
4.
Bhatt MH, Snow BJ, Martin WR, Peppard R, Calne DB. Positron emission tomography in progressive supranuclear palsy. Arch Neurol. 1991;48:389–91.
5.
Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28(4):547–55.CrossRefPubMed
6.
D’Antona R, Baron JC, Samson Y, Serdaru M, Viader F, Agid Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain. 1985;108(Pt 3):785–99.CrossRefPubMed
7.
De Volder AG, Francart J, Laterre C, Dooms G, Bol A, Michel C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol. 1989;26:239–47.CrossRefPubMed
8.
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912–21.CrossRefPubMed
9.
Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23(5):727–33.CrossRefPubMed
10.
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783–801.CrossRefPubMed
11.
Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol. 1988;24:399–406.CrossRefPubMed
12.
Gilman S, Markel DS, Koeppe RA, Junck L, Kluin KJ, Gebarski SS, et al. Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol. 1988;23:223–30.CrossRefPubMed
13.
Hagberg G, Gefvert O, Bergström M, Wieselgren IM, Lindström L, Wiesel FA, et al. N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res. 1998;82(3):147–60.CrossRefPubMed
14.
Hellwig S, Amtage F, Kreft A, Winz OH, Vach W, Spehl TS, et al. [18F]FDG-PET is superior to [123I]IBZMSPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79:1314–22.CrossRefPubMed
15.
Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci. 2002;199:67–71.CrossRefPubMed
16.
Ishiwata K, Hayakawa N, Ogi N, Oda K, Toyama H, Endo K, et al. Comparison of three PET dopamine D2-like receptor ligands, [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone, in rats. Ann Nucl Med. 1999;13(3):161–7.CrossRefPubMed
17.
Ishiwata K, Ogi N, Hayakawa N, Umegaki H, Nagaoka T, Oda K, et al. Positron emission tomography and ex vivo and in vitro autoradiography studies on dopamine D2-like receptor degeneration in the quinolinic acid-lesioned rat striatum: comparison of [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone. Nucl Med Biol. 2002;29(3):307–16.CrossRefPubMed
18.
Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol. 2004;51(3):223–33.CrossRefPubMed
19.
Juh R, Pae CU, Kim TS, Lee CU, Choe B, Suh T. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett. 2005;383:22–7.CrossRefPubMed
20.
Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol. 1992;239:98–102.CrossRefPubMed
21.
Leenders KL, Frackowiak RS, Lees AJ. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain. 1988;111(Pt 3):615–30.CrossRefPubMed
22.
Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55(1):97–105.
23.
Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, et al. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain. 2008;131:438–46.CrossRefPubMed
24.
Nagahama Y, Fukuyama H, Turjanski N, Kennedy A, Yamauchi H, Ouchi Y, et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord. 1997;12(5):691–6.CrossRefPubMed
25.
26.
Ogawa M, Fukuyama H, Harada K, Kimura J. Cerebral blood flow and metabolism in multiple system atrophy of the Shy-Drager syndrome type: a PET study. J Neurol Sci. 1998;158(2):173–9.CrossRefPubMed
27.
Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson’s disease: a positron emission tomographic study. J Neurol Sci. 1996;144(1–2):77–83.CrossRefPubMed
28.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5(4):584–90.
29.
Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, et al. Clinical metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. Arch Neurol. 1995;52:179–85.CrossRefPubMed
30.
Rosenthal G, Gilman S, Koeppe RA, Kluin KJ, Markel DS, Junck L, et al. Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography. Ann Neurol. 1988;24:414–9.CrossRefPubMed
31.
Takahashi R, Ishii K, Kakigi T, Yokoyama K, Mori E, Murakamic T. Brain alterations and mini-mental state examination in patients with progressive supranuclear palsy: Voxel-based investigations using 18F-Fluorodeoxyglucose positron emission tomography and magnetic resonance imaging. Dement Geriatr Cogn Dis Extra. 2011; 1(1):381–92.
32.
Taniwaki T, Nakagawa M, Yamada T, Yoshida T, Ohyagi Y, Sasaki M, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci. 2002;200:79–84.CrossRefPubMed
33.
Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149–58.
34.
Wagner HN, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983;221:1264–6.CrossRefPubMed
Metadata
Title
A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016)
Reply to Jean-Claude Baron Letter to Editor
Author
Marios Politis
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3597-9

Other articles of this Issue 3/2017

European Journal of Nuclear Medicine and Molecular Imaging 3/2017 Go to the issue

Original Article

On the accuracy and reproducibility of a novel probabilistic atlas-based generation for calculation of head attenuation maps on integrated PET/MR scanners

Editorial Commentary

FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future

Erratum

Erratum to: Role of PET/CT in malignant pediatric lymphoma

Original Article

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline

Image of the Month

Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging

Review Article

Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks